Equities

Shandong Lukang Pharmaceutical Co Ltd

600789:SHH

Shandong Lukang Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)6.81
  • Today's Change-0.13 / -1.87%
  • Shares traded33.51m
  • 1 Year change+1.19%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments531388578
Total Receivables, Net1,3901,261887
Total Inventory1,4061,4811,208
Prepaid expenses527778
Other current assets, total2683030.51
Total current assets3,6483,5092,751
Property, plant & equipment, net3,8874,0473,921
Goodwill, net------
Intangibles, net831749736
Long term investments157158133
Note receivable - long term172144135
Other long term assets------
Total assets8,8028,7287,822
LIABILITIES
Accounts payable9401,101796
Accrued expenses2669854
Notes payable/short-term debt1,5161,8981,688
Current portion long-term debt/capital leases453622673
Other current liabilities, total341411267
Total current liabilities3,5174,1293,478
Total long term debt1,309867693
Total debt3,2783,3863,054
Deferred income tax------
Minority interest130150145
Other liabilities, total235224223
Total liabilities5,1915,3714,539
SHAREHOLDERS EQUITY
Common stock896887881
Additional paid-in capital1,6831,6301,653
Retained earnings (accumulated deficit)1,047849755
Treasury stock - common------
Unrealized gain (loss)(15)(9.59)(5.58)
Other equity, total------
Total equity3,6123,3573,283
Total liabilities & shareholders' equity8,8028,7287,822
Total common shares outstanding896887881
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.